MicroRNAs: Novel mediators of resistance to microtubule-targeting agents

Cancer Treatment Reviews

Volumn 39, Issue 2, 2013, Pages 161-170

  Kanakkanthara, Arun ^a   Miller, John H ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Cancer cells; Drug resistance; MicroRNAs; Microtubule targeting agents

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; LET 7 PROTEIN; MICRORNA; MICRORNA 122; MICRORNA 125B; MICRORNA 135A; MICRORNA 138; MICRORNA 148A; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 181B; MICRORNA 200BC; MICRORNA 200C; MICRORNA 203; MICRORNA 21; MICRORNA 22; MICRORNA 27A; MICRORNA 337-3P; MICRORNA 34A; MICRORNA 34C; MICRORNA 429; MICRORNA 497; MICROTUBULE TARGETING AGENT; PACLITAXEL; PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

APOPTOSIS; BIOGENESIS; CANCER RESISTANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; MICROTUBULES; NEOPLASMS;

EID: 84869488084     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.07.005     Document Type: Review

References (157)

1. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
2. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010, 10:194-204.
3. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Grundhoff A., Sullivan C.S. Virus-encoded microRNAs. Virology 2011, 411:325-343.
6. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
7. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906.
8. Pasquinelli A.E., Reinhart B.J., Slack F., Martindale M.Q., Kuroda M.I., Maller B., et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000, 408:86-89.
9. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
10. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011, 39:D152-D157.
11. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human microRNA targets. PLoS Biol 2004, 2:e363.
12. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
13. Rodriguez A., Griffiths-Jones S., Ashurst J.L., Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004, 14:1902-1910.
14. Baskerville S., Bartel D.P. Microarray profiling of microRNAs reveals frequent coexpression with neighbouring miRNAs and host genes. RNA 2005, 11:241-247.
15. Griffiths-Jones S., Grocock R.J., van Dongen S., Bateman A., Enright A.J. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006, 34:D140-D144.
16. Griffiths-Jones S., Bateman A., Marshall M., Khanna A., Eddy S.R. Rfam: an RNA family database. Nucleic Acids Res 2003, 31:439-441.
17. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H., et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004, 23:4051-4060.
18. Borchert G.M., Lanier W., Davidson B.L. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006, 13:1097-1101.
19. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., et al. The nuclear RNase III drosha initiates microRNA processing. Nature 2003, 425:415-419.
20. Gregory R.I., Yan K.P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004, 432:235-240.
21. Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011-3016.
22. Chendrimada T.P., Gregory R.I., Kumaraswamy E., Norman J., Cooch N., Nishikura K., et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436:740-744.
23. Maniataki E., Mourelatos Z. A human, ATP-independent, RISC assembly machine fueled by pre-miRNA. Genes Dev 2005, 19:2979-2990.
24. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
25. Vasudevan S. Posttranscriptional upregulation by microRNAs. Wiley Interdiscip Rev RNA 2012, 3:311-330.
26. Gorospe M., Tominaga K., Wu X., Fähling M., Ivan M. Post-transcriptional control of the hypoxic response by RNA-binding proteins and microRNAs. Front Mol Neurosci 2011, 4:7.
27. Bagga S., Bracht J., Hunter S., Massirer K., Holtz J., Eachus R., et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005, 122:553-563.
28. Behm-Ansmant I., Rehwinkel J., Doerks T., Stark A., Bork P., Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 2006, 20:1885-1898.
29. Zeng Y., Wagner E.J., Cullen B.R. Both natural and designed microRNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002, 9:1327-1333.
30. Palatnik J.F., Allen E., Wu X., Schommer C., Schwab R., Carrington J.C., et al. Control of leaf morphogenesis by microRNAs. Nature 2003, 425:257-263.
31. Tang G., Reinhart B.J., Bartel D.P., Zamore P.D. A biochemical framework for RNA silencing in plants. Genes Dev 2003, 17:49-63.
32. Brennecke J., Hipfner D.R., Stark A., Russell R.B., Cohen S.M. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003, 113:25-36.
33. Pillai R.S., Bhattacharyya S.N., Artus C.G., Zoller T., Cougot N., Basyuk E., et al. Inhibition of translational initiation by let-7 microRNA in human cells. Science 2005, 309:1573-1576.
34. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000, 69:277-302.
35. Desai A., Mitchison T.J. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997, 13:83-117.
36. Rusan N.M., Fagerstrom C.J., Yvon A.M., Wadsworth P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein α-tubulin. Mol Biol Cell 2001, 12:971-980.
37. Holy T.E., Leibler S. Dynamicinstability of microtubules as an efficient way to search in space. Proc Natl Acad Sci U S A 1994, 91:5682-5685.
38. Mimori-Kiyosue Y., Tsukita S. " Search-and-capture" of microtubules through plus-end-binding proteins (+TIPs). J Biochem 2003, 134:321-326.
39. Mitchison T.J. Microtubule dynamics and kinetochore function in mitosis. Annu Rev Cell Biol 1988, 4:527-549.
40. Kops G.J. The kinetochore and spindle checkpoint in mammals. Front Biosci 2008, 13:3606-3620.
41. Dumontet C., Jordan M.A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010, 9:790-803.
42. Ganguly A., Yang H., Cabral F. Paclitaxel-dependent cell lines reveal a novel drug activity. Mol Cancer Ther 2010, 9:2914-2923.
43. Yang H., Ganguly A., Cabral F. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem 2010, 285:32242-32250.
44. Nogales E., Wolf S.G., Downing K.H. Structure of the αβ tubulin dimer by electron crystallography. Nature 1998, 391:199-203.
45. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zaharevitz D., Bollbuck B., et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000, 97:2904-2909.
46. Kanakkanthara A., Wilmes A., O'Brate A., Escuin D., Chan A., Gjyrezi A., et al. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Mol Cancer Ther 2011, 10:1419-1429.
47. Bhattacharyya B., Panda D., Gupta S., Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008, 28:155-183.
48. Gupta S., Bhattacharyya B. Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem 2003, 253:41-47.
49. Shoemaker A.R., Oleksijew A., Bauch J., Belli B.A., Borre T., Bruncko M., et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006, 66:8731-8739.
50. Patel N., Chatterjee S.K., Vrbanac V., Chung I., Mu C.J., Olsen R.R., et al. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci U S A 2010, 107:2503-2508.
51. Arai T., Miyoshi Y., Kim S.J., Akazawa K., Maruyama N., Taguchi T., et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008, 34:734-738.
52. Reed J.C., Miyashita T., Takayama S., Wang H.G., Sato T., Krajewski S., et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996, 60:23-32.
53. Sharpe J.C., Arnoult D., Youle R.J. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004, 1644:107-113.
54. Gazitt Y., Rothenberg M.L., Hilsenbeck S.G., Fey V., Thomas C., Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998, 13:839-848.
55. Strobel T., Swanson L., Korsmeyer S., Cannistra S.A. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 1996, 93:14094-14099.
56. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003, 22:9075-9086.
57. Sorrentino A., Liu C.G., Addario A., Peschle C., Scambia G., Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008, 111:478-486.
58. Zhou M., Liu Z., Zhao Y., Ding Y., Liu H., Xi Y., et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010, 285:21496-21507.
59. Schotte D., De Menezes R.X., Moqadam F.A., Khankahdani L.M., Lange-Turenhout E., Chen C., et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011, 96:703-711.
60. Shi X.B., Xue L., Yang J., Ma A.H., Zhao J., Xu M., et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007, 104:19983-19988.
61. Zhang H., Luo X.Q., Feng D.D., Zhang X.J., Wu J., Zheng Y.S., et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011, 10:108.
62. Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010, 70:1501-1512.
63. Kastl L., Brown I., Schofield A.C. MiRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 2012, 131:445-454.
64. Han E.K., Ng S.C., Arber N., Begemann M., Weinstein I.B. Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis. Apoptosis 1999, 4:213-219.
65. Lukas J., Pagano M., Staskova Z., Draetta G., Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994, 9:707-718.
66. Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 2012, in press, doi:10.1038/onc.2012.51.
67. Chen Y., Zuo J., Liu Y., Gao H., Liu W. Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer 2010, 29:1006-1011.
68. Li L., Backer J., Wong A.S., Schwanke E.L., Stewart B.G., Pasdar M. Bcl-2 expression decreases cadherin-mediated cell-cell adhesion. J Cell Sci 2003, 116:3687-3700.
69. Li Z., Wang L., Zhang W., Fu Y., Zhao H., Hu Y., et al. Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells. Biochem Biophys Res Commun 2007, 363:165-170.
70. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245.
71. Tanaka M., Grossman H.B. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene ther 2003, 10:1636-1642.
72. Han Z., Hong L., Han Y., Wu K., Han S., Shen H., et al. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 2007, 26:261-268.
73. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
74. Ren Y., Zhou X., Mei M., Yuan X.B., Han L., Wang G.X., et al. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010, 10:27.
75. Meng W., Jiang L., Lu L., Hu H., Yu H., Ding D., et al. Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biol Int 2012, 36:653-659.
76. Mei M., Ren Y., Zhou X., Yuan X.B., Han L., Wang G.X., et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 2010, 9:77-86.
77. Borowiec A.S., Hague F., Harir N., Guénin S., Guerineau F., Gouilleux F., et al. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation. J Cell Physiol 2007, 212:690-701.
78. Weber C., Mello de Queiroz F., Downie B.R., Suckow A., Stühmer W., Pardo L.A. Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference. J Biol Chem 2006, 281:13030-13037.
79. Li J., Zhang Y., Zhao J., Kong F., Chen Y. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 2011, 357:31-38.
80. Li J., Chen Y., Zhao J., Kong F., Zhang Y. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 2011, 304:52-59.
81. Huang W.C., Hung M.C. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009, 108:180-194.
82. McDonald G.T., Sullivan R., Paré G.C., Graham C.H. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp Cell Res 2010, 316:3197-3206.
83. Blanco-Aparicio C., Renner O., Leal J.F., Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007, 28:1379-1386.
84. Hu G., Chong R.A., Yang Q., Wei Y., Blanco M.A., Li F., et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009, 15:9-20.
85. Hu G., Wei Y., Kang Y. The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res 2009, 15:5615-5620.
86. Tsang W.P., Kwok T.T. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008, 13:1215-1222.
87. Lu L., Schwartz P., Scarampi L., Rutherford T., Canuto E.M., Yu H., et al. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol 2011, 122:366-371.
88. Fujita Y., Kojima K., Ohhashi R., Hamada N., Nozawa Y., Kitamoto A., et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010, 285:19076-19084.
89. Wiggin G.R., Soloaga A., Foster J.M., Murray-Tait V., Cohen P., Arthur J.S. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 2002, 22:2871-2881.
90. Soloaga A., Thomson S., Wiggin G.R., Rampersaud N., Dyson M.H., Hazzalin C.A., et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 2003, 22:2788-2797.
91. Tan T.T., Degenhardt K., Nelson D.A., Beaudoin B., Nieves-Neira W., Bouillet P., et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005, 7:227-238.
92. Lu M., Xiao L., Hu J., Deng S., Xu Y. Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells. J Huazhong Univ Sci Technol Med Sci 2008, 28:451-455.
93. Holleman A., Chung I., Olsen R.R., Kwak B., Mizokami A., Saijo N., et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011, 30:4386-4398.
94. Zhang T., Otevrel T., Gao Z., Ehrlich S.M., Fields J.Z., Boman B.M. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001, 61:8664-8667.
95. Du L., Subauste M.C., Desevo C., Zhao Z., Baker M., Borkowski R., et al. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012, 7:e39167.
96. Pensa S., Regis G., Boselli D., Novelli F., Poli V. STAT1 and STAT3 in tumorigenesis: two sides of the same coin?. JAKSTAT pathway in disease 2000, Landes Bioscience, Austin, TX. A. Stephanou (Ed.).
97. Kim D.J., Chan K.S., Sano S., Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 2007, 46:725-731.
98. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 2006, 6:107-121.
99. Fujita H., Fukuhara S., Sakurai A., Yamagishi A., Kamioka Y., Nakaoka Y., et al. Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes. J Biol Chem 2005, 280:5022-5031.
100. Pizon V., Baldacci G. Rap1A protein interferes with various MAP kinase activating pathways in skeletal myogenic cells. Oncogene 2000, 19:6074-6081.
101. Hoshi M., Ohta K., Gotoh Y., Mori A., Murofushi H., Sakai H., et al. Mitogen activated-protein-kinase-catalyzed phosphorylation of microtubule-associated proteins, microtubule-associated protein 2 and microtubule-associated protein 4, induces an alteration in their function. Eur J Biochem 1992, 203:43-52.
102. Kinbara K., Goldfinger L.E., Hansen M., Chou F.L., Ginsberg M.H. Ras GTPases: integrins' friends or foes?. Nat Rev Mol Cell Biol 2003, 4:767-776.
103. Ahmed A.A., Mills A.D., Ibrahim A.E., Temple J., Blenkiron C., Vias M., et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 2007, 12:514-527.
104. Zhu W., Shan X., Wang T., Shu Y., Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127:2520-2529.
105. Zhu W., Zhu D., Lu S., Wang T., Wang J., Jiang B., et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012, 9:384-391.
106. Zhu W., Xu H., Zhu D., Zhi H., Wang T., Wang J., et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012, 69:723-731.
107. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 15(123):372-379.
108. Rui W., Bing F., Hai-Zhu S., Wei D., Long-Bang C. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010, 14:206-214.
109. Boren T., Xiong Y., Hakam A., Wenham R., Apte S., Chan G., et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009, 113:249-255.
110. Dai Y., Xie C.H., Neis J.P., Fan C.Y., Vural E., Spring P.M. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011, 33:786-791.
111. Boyerinas B., Park S.M., Murmann A.E., Gwin K., Montag A.G., Zillhardt M., et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012, 130:1787-1797.
112. Zhang H., Li M., Han Y., Hong L., Gong T., Sun L., et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010, 55:2545-2551.
113. Li Z., Hu S., Wang J., Cai J., Xiao L., Yu L., et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010, 119:125-130.
114. Zhao X., Yang L., Hu J., Ruan J. miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010, 34:1078-1082.
115. Xu Y., Xia F., Ma L., Shan J., Shen J., Yang Z., et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011, 310:160-169.
116. Kanakkanthara A., Northcote P.T., Miller J.H. β II-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Mol Cancer Ther 2012, 11:393-404.
117. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8:1055-1066.
118. Cochrane D.R., Howe E.N., Spoelstra N.S., Richer J.K. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol 2010, 2010:821717.
119. Leskelä S., Leandro-García L.J., Mendiola M., Barriuso J., Inglada-Pérez L., Muñoz I., et al. The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2010, 18:85-95.
120. Lobert S., Jefferson B., Morris K. Regulation of β-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells. Cytoskeleton (Hoboken) 2011, 68:355-362.
121. Gan P.P., Kavallaris M. Tubulin-targeted drug action: functional significance of class II and class IVb β-tubulin in vinca alkaloid sensitivity. Cancer Res 2008, 68:9817-9824.
122. Bhattacharya R., Frankfurter A., Cabral F. A minor β-tubulin essential for mammalian cell proliferation. Cell Motil Cytoskeleton 2008, 65:708-720.
123. Nagaraja A.K., Creighton C.J., Yu Z., Zhu H., Gunaratne P.H., Reid J.G., et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010, 24:447-463.
124. Zumbrunn J., Kinoshita K., Hyman A.A., Näthke I.S. Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 beta phosphorylation. Curr Biol 2001, 11:44-49.
125. Näthke I. Relationship between the role of the adenomatous polyposis coli protein in colon cancer and its contribution to cytoskeletal regulation. Biochem Soc Trans 2005, 33:694-697.
126. Huang L., Lin J.X., Yu Y.H., Zhang M.Y., Wang H.Y., Zheng M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One 2012, 7:e33762.
127. Gallardo E., Navarro A., Viñolas N., Marrades R.M., Diaz T., Gel B., et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009, 30:1903-1909.
128. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
129. Donnem T., Fenton C.G., Lonvik K., Berg T., Eklo K., Andersen S., et al. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One 2012, 7:e29671.
130. Wang X.C., Du L.Q., Tian L.L., Wu H.L., Jiang X.Y., Zhang H., et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung cancer 2011, 72:92-99.
131. Gao W., Shen H., Liu L., Xu J., Xu J., Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011, 137:557-566.
132. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
133. Zheng D., Haddadin S., Wang Y., Gu L.Q., Perry M.C., Freter C.E., et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011, 4:575-586.
134. Qian P., Zuo Z., Wu Z., Meng X., Li G., Wu Z., et al. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res 2011, 71:6463-6474.
135. Landi M.T., Zhao Y., Rotunno M., Koshiol J., Liu H., Bergen A.W., et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010, 16:430-441.
136. Zheng B., Liang L., Wang C., Huang S., Cao X., Zha R., et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 2011, 17:7574-7583.
137. Navarro A., Diaz T., Martinez A., Gaya A., Pons A., Gel B., et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009, 114:2945-2951.
138. Visone R., Veronese A., Balatti V., Croce C.M. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget 2012, 3:195-202.
139. Han B.W., Feng D.D., Li Z.G., Luo X.Q., Zhang H., Li X.J., et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 2011, 20:4903-4915.
140. Lehmann U., Hasemeier B., Christgen M., Müller M., Römermann D., Länger F., et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008, 214:17-24.
141. Lujambio A., Calin G.A., Villanueva A., Ropero S., Sánchez-Céspedes M., Blanco D., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008, 105:13556-13561.
142. Bueno M.J., Pérez de Castro I., Gómez de Cedrón M., Santos J., Calin G.A., Cigudosa J.C., et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13:496-506.
143. Ji J., Yamashita T., Wang X.W. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci 2011, 1:4.
144. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752.
145. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
146. Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
147. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006, 103:9136-9141.
148. Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004, 64:3087-3095.
149. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
150. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
151. Lu Y., Roy S., Nuovo G., Ramaswamy B., Miller T., Shapiro C., et al. Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011, 286:42292-42302.
152. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011, 19:1116-1122.
153. Takeshita F., Patrawala L., Osaki M., Takahashi R.U., Yamamoto Y., Kosaka N., et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010, 18:181-187.
154. Ibrahim A.F., Weirauch U., Thomas M., Grünweller A., Hartmann R.K., Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011, 71:5214-5224.
155. Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, et al., microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cε. Oncogene 2011, in press, doi:10.1038/onc.2011.565.
156. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9:775-789.
157. Melo S., Villanueva A., Moutinho C., Davalos V., Spizzo R., Ivan C., et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A 2011, 108:4394-4399.